Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337

Showing 1-25 of 337 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1158
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 675
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 321
Diabetes Fact Sheet in Korea 2021
Jae Hyun Bae, Kyungdo Han, Seung‐Hyun Ko, et al.
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 3, pp. 417-426
Open Access | Times Cited: 275
Diabetes and Stroke: What Are the Connections?
Ofri Mosenzon, Alice Cheng, Alejandro A. Rabinstein, et al.
Journal of Stroke (2023) Vol. 25, Iss. 1, pp. 26-38
Open Access | Times Cited: 107
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
Dario Giugliano, Miriam Longo, Simona Signoriello, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 99
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
Aditi R. Saxena, Juan P. Frías, Lisa Brown, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2314493-e2314493
Open Access | Times Cited: 83
Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 6, pp. 767-773
Open Access | Times Cited: 80
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes
Magdalena Wronka, Julia Krzemińska, Ewelina Młynarska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15743-15743
Open Access | Times Cited: 71
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Saleh Hadi Alharbi
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 68
Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
Erin D. Michos, George L. Bakris, Helena W. Rodbard, et al.
American Journal of Preventive Cardiology (2023) Vol. 14, pp. 100502-100502
Open Access | Times Cited: 65
Association between the systemic immune-inflammation index and kidney stone: A cross-sectional study of NHANES 2007-2018
Xingpeng Di, Shaozhuang Liu, Liyuan Xiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 60
Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2096-2106
Closed Access | Times Cited: 54
Adverse Events Related to Tirzepatide
Rahul Mishra, Rishi Raj, Ghada Elshimy, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 51
Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review
Bronya Calvarysky, I Dotan, Daniel Shepshelovich, et al.
Drug Safety (2024) Vol. 47, Iss. 5, pp. 439-451
Open Access | Times Cited: 19
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 18
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 331-341
Open Access | Times Cited: 53
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda, Lawrence Blonde, Richard E. Pratley
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 5, pp. 979-994
Open Access | Times Cited: 49
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
Yaofu Zhang, Li Jiang, Junheng Wang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 49
The Role of Obesity and Diabetes in Dementia
Ashley Selman, Scott Burns, Arubala P. Reddy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9267-9267
Open Access | Times Cited: 48
Efficacy of Personalized Diabetes Self-care Using an Electronic Medical Record–Integrated Mobile App in Patients With Type 2 Diabetes: 6-Month Randomized Controlled Trial
Eun Young Lee, Seon‐Ah Cha, Jae‐Seung Yun, et al.
Journal of Medical Internet Research (2022) Vol. 24, Iss. 7, pp. e37430-e37430
Open Access | Times Cited: 45
Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Baptist Gallwitz
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 45
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial
Monika Kellerer, Margit S. Kaltoft, Jack Lawson, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 9, pp. 1788-1799
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top